KDP1

KDP1 is an experimental **biotin-conjugated BODIPY photosensitizer** designed for targeted photodynamic therapy and cancer imaging. In the cited preclinical study, KDP1 was one of two mitochondria-targeted BODIPY-biotin conjugates with strong light absorption, measurable singlet oxygen generation, mitochondrial localization, and potent photocytotoxicity in MDA-MB-231 breast cancer cells at nanomolar concentrations. Its antitumor activity appears to depend on light activation, reactive oxygen species generation, and induction of apoptosis rather than on a validated single molecular target. No evidence from the provided context establishes commercial development, clinical testing, branding, or a named corporate developer for KDP1.